Moxivar Dosage/Direction for Use

Dosage: The recommended dose for moxifloxacin is 400 mg once daily.
No adjustment of dosage is required in elderly patients.
Efficacy and safety in children and adolescents have not been established.
No dosage adjustment is required in patients with any degree of renal impairment (including creatinine clearance ≤ 30 mL/minute/1.73m²).
For treatment of complicated intra-abdominal infections and complicated skin and skin structure infections requiring initial intravenous therapy followed by oral administration of 400 mg moxifloxacin tablet.
Administration: The infusion solution should be infused intravenously over 1 hour. Rapid intravenous infusion of moxifloxacin should be avoided.
It can be administered directly or via a T-tube together with compatible infusion solutions.
If moxifloxacin infusion solution is to be given with another drug, each drug should be given separately.
Moxifloxacin intravenous solution should be in inspected visually for particulate matter prior to administration and should be discarded if visible particulates are evident. Only clear solutions are to be used.
Duration of treatment: The duration of treatment should be determined by the severity of the indication of clinical response. The following are general recommendations: Acute exacerbation of chronic bronchitis: 5-10 days.
Community acquired pneumonia: 10 days.
Acute sinusitis: 7 days.
Complicated skin and skin structure infections: 7-21 days (sequential intravenous/oral therapy).
Complicated intra-abdominal infections: 5-14 days (sequential intravenous/oral therapy).
In patients with complicated skin and skin structure infections, the mean duration of intravenous therapy was approximately 6 days with overall mean treatment duration of approximately 13 days.
Moxifloxacin can be administered intravenously as initial intravenous administration, followed by oral tablet administration when allowed by the patient's condition. The recommended dose (400 mg once daily) and duration of therapy for indication being treated should not be exceeded. Intravenous therapy may be limited for up to 2-5 days in therapy in the very ill patients and should be changed to oral therapy whenever possible as determined by the physician.